Swing Therapeutics, a San Francisco, CA-based digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, raised $9m in seed funding.
The round was led by Jazz Venture Partners.
The company also announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s digital therapeutic for the management of fibromyalgia. Swing Therapeutics is also launching a real-world study of its digital therapeutic, which is based on a clinically validated program that it exclusively licensed from the University of Manitoba.
Swing’s program digitally delivers acceptance and commitment therapy (ACT), a form of cognitive behavioral therapy (CBT). Its daily digital therapeutic includes engaging lessons and interactive exercises that help patients apply well-established principles to their unique circumstances and gradually develop the ability to manage their condition. The self-guided program is designed to foster understanding and acceptance of the participants’ own symptoms, while teaching powerful condition management skills. The program being studied also incorporates a tool to help users triage symptom flares—a common occurrence with fibromyalgia. The core program lasts 12 weeks, with a maintenance mode for extended use.
Led by Mike Rosenbluth, Ph.D., founder and CEO, Swing Therapeutics is currently initiating a clinical trial called REACT-FM (Real-World Evidence from Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia).